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Abstract
Background: Familial breast cancer (BC) represents 5 to 10% of all BC cases. Mutations in two high susceptibility BRCA1
and BRCA2 genes explain 16–40% of familial BC, while other high, moderate and low susceptibility genes explain up to
20% more of BC families. The Lebanese reported prevalence of BRCA1 and BRCA2 deleterious mutations (5.6% and 12.5%)
were lower than those reported in the literature.
Methods: In the presented study, 45 Lebanese patients with a reported family history of BC were tested using Whole
Exome Sequencing (WES) technique followed by Sanger sequencing validation.
Results: Nineteen pathogenic mutations were identified in this study. These 19 mutations were found in 13 different
genes such as: ABCC12, APC, ATM, BRCA1, BRCA2, CDH1, ERCC6, MSH2, POLH, PRF1, SLX4, STK11 and TP53.
Conclusions: In this first application of WES on BC in Lebanon, we detected six BRCA1 and BRCA2 deleterious mutations
in seven patients, with a total prevalence of 15.5%, a figure that is lower than those reported in the Western literature. The
p.C44F mutation in the BRCA1 gene appeared twice in this study, suggesting a founder effect. Importantly, the overall
mutation prevalence was equal to 40%, justifying the urgent need to deploy WES for the identification of genetic variants
responsible for familial BC in the Lebanese population.
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Background
Breast cancer (BC) is the most common cancer in women,
accounting for around 25% of all new cases of cancer [1].
Most BC cases are sporadic, while 5 to 10% of all BC cases
are inherited and cluster in families [1]. While mutations in
BRCA1 and BRCA2 genes explain 16–40% of all familial
BC cases [1–3], other genes have also been found to in-
crease BC susceptibility, which highlights the polygenic
nature of many BC cases [4]. Some of these genes including
CDH1, TP53, PTEN and STK11, although less frequently
altered compared to the BRCA1/2 genes, they have been
linked to high-penetrance autosomal dominant BC [5–7].
Moderate penetrance genes are implicated in around 5% of
familial BC. These genes include the Fanconi anemia path-
way genes: FANCA, PALB2, BRIP1, RAD51C and XRCC2
[8–10] and non-Fanconi anemia genes: ATM, CHEK2,
NBN, RAD50, RAD51B, and RAD51D [11–15].
In Lebanon, BC is the most common cancer type in
females and it constitutes one-third of all reported can-
cer cases. BC incidence rates are expected to reach 137
per 100,000 by 2018 [16]. Yet, to date, only two studies
have investigated the role of BRCA1 and BRCA2 muta-
tions in the Lebanese population. These studies reported
varied prevalence of pathogenic BRCA mutations ran-
ging between 5.6 to 12.5% in BC cases [17, 18]. The re-
ported prevalences of both BRCA1 and BRCA2
deleterious mutations were lower than those reported
for the Western populations, which suggest the involve-
ment of other genes in the pathogenesis of BC cases
[19]. The reported low prevalence does not support the
hypothesis that BRCA1 and BRCA2 mutations alone are
responsible for the majority of the observed Lebanese
women with early-onset BC. This finding could well
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genetic heterogeneity and that monogenic and polygenic
models of inheritance may exist.
Since the completion of the human genome project,
massive leaps have reshaped the field of clinical genom-
ics. The development of Next-generation sequencing
(NGS) platforms allowed a more robust, fast and accur-
ate analysis of diseases and syndromes with polygenic
nature. NGS platforms including WES are believed to
enhance and improve diagnosis and therapy develop-
ment of many diseases including BC [20–23].
In the presented study, we utilized WES to investigate
germline genetic variations in 45 Lebanese cases diag-
nosed with familial BC and unknown BRCA1 or BRCA2
status. We found several rare variants that can poten-
tially explain BC susceptibility in the analyzed cases.
Methods
Inclusion criteria
From 2012 to 2015, 45 unrelated patients with inherited
BC were selected to undergo DNA testing. They were
referred from a wide variety of settings from all over the
country, ranging from private physicians’ clinics to major
academic medical centers because of hereditary BC. The
patients fulfilled a personal history of invasive BC and at
least one of the following criteria: A) diagnosis at age ≤
40 years, B) BC at any age at onset with at least 2 first-
and/or second-degree relatives, C) BC < 50 years in a
first- or second-degree relative, D) ovarian cancer in at
least 2 first- and/or second-degree relatives, E) breast
and ovarian cancer in at least 2 first- and/or second-
degree relatives, F) both breast and ovarian cancer in a
single first- or second-degree relative.
Approval to conduct the study was obtained from the
Ethics Committee of Saint-Joseph University-Lebanon.
After an informed consent was signed and all ethical
requirements were fulfilled, a 10 ml of peripheral blood
was isolated from each individual enrolled and the DNA
was extracted using the salting out methods [24]. All pa-
tients signed the informed consent and agreed to share
their variant data.
Whole exome sequencing
Exon capture and sequencing: Samples were prepared
for whole Exome sequencing and enriched according to
the manufacturer’s standard protocol. The concentration
of each library was determined using Agilent’s QPCR
NGS Library Quantification Kit (G4880A). Samples were
pooled prior to sequencing with each sample at a final
concentration of 10nM. Sequencing was performed on
the Illumina HiSeq2000 platform using TruSeq v3
chemistry.
Mapping and alignment: Reads files (FASTQ) were
generated from the sequencing platform via the manu-
facturer’s proprietary software. Reads were aligned to the
hg19/b37 reference genome using the Burrows-Wheeler
Aligner (BWA) package v0.6.1 [25]. Local realignment of
the mapped reads around potential insertion/deletion
(Indel) sites was carried out with the Genome Analysis
Tool Kit (GATK) v1.6 [26]. Duplicate reads were marked
using Picard v1.62. Additional BAM file manipulations
were performed with Samtools 0.1.18 [27]. Base quality
(Phred scale) scores were recalibrated using GATK’s co-
variance recalibration. SNP and Indel variants called
using the GATK Unified Genotyper for each sample
[28]. SNP novelty is determined against dbSNP. A list of
134 genes known to be associated with hereditary BC
and other cancers were studied (Additional file 1).
Variants evaluation
Variants obtained were reported using five categories ac-
cording to the Human Genome Mutation Database
(HGMD Professional) [29]. These categories are listed in
Table 1.
The first variant category consists of alleles labeled as
disease causing mutations (DM) in HGMD Professional.
These alleles must be rare: <1% allele frequency in 6,500
exomes from the National Heart, Lung, and Blood Insti-
tute (NHLBI) Exome Sequencing Project (“Exome Vari-
ant Server” 2015) and the 1,000 Genomes Project
Genomes [30].
The BRCA gene variants identified were checked for
pathogenicity in 4 databases: Breast Cancer Information
Core (BIC) [31], Leiden Open Variation Database
(LOVD) [32], the Catalogue of Somatic Mutations in
Cancer database (COSMIC) [33] and BRCA Exchange
website (http://brcaexchange.org) providing data from
the ENIGMA consortium [34].
Table 1 Variants reported in five categories according to the
HGMD Professional
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association with disease (p < 0.05)
that has evidence of being of
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reported as yet
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Variants confirmation
Sanger’s sequencing was utilized to confirm the rele-
vant variants identified by WES and to study the seg-
regation of these variants with the disease phenotype
in members of families included in the study. PCR
reactions were run in final volumes of 50 μl containing
100 ng DNA, 0.25 mM dNTPs, 100 ng of each primer
and 0.02 unit of Taq polymerase (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA). PCR was performed in
an ABI9700 thermocycler (Applied Biosystems, Foster
City, CA) with initial denaturation at 94 °C for 5 min,
followed by 35 cycles of 95 °C for 30s, specific anneal-
ing temperature for 30s, 72 °C for 30s. Primer
sequences are available on request as well as annealing
temperatures of each exon. PCR products were puri-
fied using the illustraTM GFX PCR DNA and Gel
Band Purification Kit (GE Healthcare, Buckingham-
shire, UK). Both strands of the products were se-
quenced using the BigDyeW Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA)
under standard conditions. The labeled products were
subjected to electrophoresis on an ABI3130 and
ABI3500 Genetic Analyzer sequencing system
(Applied Biosystems, Foster City, CA, USA). Electro-
pherograms were analyzed using Sequence Analysis
Software v5.2 (Applied Biosystems, Foster City, CA,
USA) and compared to reference sequences using
ChromasPro v1.7.6.1 (Technelysium, Queensland,
Australia).
Results
Patient characteristics and sequencing statistics
The mean age at diagnosis of BC for the 45 patients was
44 years (range 29–79). Sixteen patients provided us
with their histopathological results. Seven BC were
estrogen-receptor (ER) and progesterone-receptor (PR)
positive, 5 patients had negative ER and PR disease and
2 patients had negative ER and positive PR disease. Two
patients had triple negative disease from which one
patient (Family 30) carried p.C44F mutation in BRCA1
(Fig. 1).
We obtained an average of 44 million reads per sam-
ple, with a mean coverage of 94% at a mean X coverage
of 20X.
WES analysis
Within this cohort, a total of 126 variants were detected
by WES and these are listed in Table 2. In 7 of the 45
patients, not listed in Table 2, no variants in cancer pre-
disposing genes (Additional file 1) were identified.
We were able to detect 19 HGMD DM variations of
which 9 are specifically associated with breast cancer
(Table 2). The distribution of the remaining variants in
the HGMD categories was: 11 DM?, 11 DP, 1 FP, and 9
DFP. In addition, 75 novel variations were detected in
this study (Table 2).
Six BRCA1 and BRCA2 DM mutations were detected
in 5 and 2 patients, respectively in a total prevalence of
15.5% (Table 2).
Fig. 1 Pedigrees of the families presenting DM mutations. Filled squares (males) and circles (females) indicate the affected individuals. Probands
are marked with arrows. DM mutations are bolded
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Table 2 Mutations in BC associated genes detected by NGS in a series of 45 Lebanese patients
Family number/Patient code Genes Results HGMD Professional ExAC allele frequency
1/B19 XRCC3 c.C722T p.T241M DFP Association with melanoma 0.3075
XRCC1 c.G839A p.R280H DFP Association with increased lung cancer 0.08811
CASP8 c.*429A > G Not found Not found
BRCA2 c.C65T p.A22V Not found Not found
MUTYH c.C1258G p.L420V Not found Not found
SLX4 c.C1837T p.Q613X Not found Not found
2/B21 BRCA1 c.A536G p.Y179C DM Breast and/or ovarian cancer 0.0002718
ATM c.T2572C p.F858L DP Association with breast cancer 0.009149
ATM c.C3161G p.P1054R DFP Association with breast cancer 0.01692
TP53 c.C215G p.P72R DFP Association with Lung cancer 0.6600
3/B22 BRCA2 c.C5744T p.T1915M DP Association with breast cancer risk 0.01790
ARL11 c.G446A p.W149X DP Association with cancer 0.009898
TP53 c.C215G p.P72R DFP Association with Lung cancer 0.6600
ERCC3 c.C508T p.R170X Not found Not found
VHL c.A631C p.M211L Not found 0.00004623
MRE11A c.C1491T p.I497I Not found 0.0006514
PTCH1 c.G4054A p.V1352I Not found Not found
4/B23 TP53 c.C215G p.P72R DFP Association with Lung cancer 0.6600
TP53 c.C245T p.P82L DM Breast cancer 0.00001657
BRCA2 c.A1114C p.N372H DFP Association with Breast cancer 0.2779
FANCA c.G1038C p.W346C Not found 0.00006621
POLE c.C3890T p.S1297L Not found 0.00002580
POLD1 c.T2257C p.Y753H Not found Not found
GATA2 c.C1040T p.T347I Not found Not found
5/B24 BRCA2 c.G8775C p.Q2925H Not found 0.000008322
APC c.C6821T p.A2274V DM Adenomatous polyposis coli 0.0009917
EZH2 c.C349T p.Q117X Not found Not found
6/B25 XRCC3 c.C722T p.T241M DFP Association with melanoma 0.3075
MLH1 c.A655G p.I219V DP Colorectal cancer, non-polyposis 0.2325
RAD51D c.G494A p.R165Q Not found Not found
ATM c.496 + 4 T > C Not found 0.00009891
PPM1D c.G275C p.C92S Not found Not found
STK11 c.375-1C > T DM Colorectal cancer Not found
7/B26 XRCC3 c.C722T p.T241M DFP Association with melanoma 0.3075
MSH2 c.C1045G p.P349A DM Renal cell carcinoma 0.00009062
MUTYH c.C1174A p.L392M Not found Not found
MUTYH c.C1258A p.L420M DM? Colorectal cancer Not found
ATM c.496 + 4 T > C Not found 0.00009891
RB1 c.C1505T p.T502I Not found 0.00001098
PPM1D c.G275C p.C92S Not found Not found
8/B27 XRCC3 c.C722T p.T241M DFP Association with melanoma 0.3075
BRCA1 c.A1067G p.Q356R DP Association with breast and/or
ovarian cancer
0.04407
XRCC1 c.C580T p.R194W DFP Benign breast disease 0.09276
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Table 2 Mutations in BC associated genes detected by NGS in a series of 45 Lebanese patients (Continued)
CDH1 c.G1774A p.A592T DM? Breast cancer 0.003212
35/B28 BARD1 c.1071_1091del p.357_364del Not found Not found
ABCC12 c.G490T p.G164X DM Bladder cancer 0.003185
MCC c.G152T p.G51V Not found 0.0001346
9/B31 ATM c.T2119C p.S707P DFP Association with Breast cancer 0.007927
FANCA c.C4232T p.P1411L Not found 0.0001318
36/B32 ATM c.C2770T p.R924W Not found 0.00004942
ALK c.T4211C p.L1404P Not found 0.00008370
10/B33 BRIP1 c.A3571G p.I1191V Not found 0.00004967
NSD1 c.2224_2243del p.P742fs Not found Not found
FANCG c.G1298C p.R433P Not found 0.00004118
FLCN c.T1387C p.Y463H Not found 0.00003298
PTCH1 c.A3749G p.Y1250C Not found Not found
11/B34 XRCC4 c.T401C p.I134T DP Association with Lung cancer 0.02505
RAD51C c.G376A p.A126T FP Reduced activity 0.003529
12/B35 ARL11 c.G571A p.G191R Not found 0.00002188
Rad50 c.A280C p.I94L DM? Breast and/or ovarian cancer 0.003473
POLE c.G2276A p.R759H Not found 0.00001647
13/B36 BRCA1 c.G131T p.C44F DM Breast and/or ovarian cancer Not found
SLX4 c.G421T p.G141W DM Breast and/or ovarian cancer 0.0008237
STK11 c.C1211T p.S404F DM Peutz-Jeghers syndrome 0.0009281
PALB2 c.G2993A p.G998E DP Breast cancer, increased risk- 0.01579
BRCA2 c.C1151T p.S384F DM? Breast cancer 0.0006789
DICER1 c.A5276G p.K1759R Not found 0.00004942
CEBPA c.T122C p.I41T Not found Not found
RECQL4 c.G3314A p.G1105D Not found 0.005430
14/B37 RAD50 c.G379A p.V127I Not found 0.001653
CASP8 c.A1117G p.I373V Not found Not found
RECQL4 c.C3184T p.R1062W Not found 0.0003129
WRN c.G4129A p.G1377S Not found 0.00002483
15/B38 BARD1 c.C119T p.A40V Not found 0.00004775
PTCH1 c.169_170delCT p.57_57del Not found 0.000008913
PTCH1 c.A3749G p.Y1250C Not found Not found
PTCH1 c.C4126T p.R1376W Not found Not found
ERCC5 c.A1904G p.H635R Not found Not found
DICER1 c.C3811T p.L1271F Not found Not found
16/B39 CDKN2A c.G442A p.A148T DP Association with melanoma 0.02278
RAD51D c.A758G p.E253G Not found 0.01144
ERCC6 c.C2800A p.P934T DM Cockayne syndrome Not found
17/B40 MSH2 c.A1787G p.N596S DM Colorectal cancer, non-polyposis 0.0002558
ATM c.A1982C p.D661A Not found Not found
PMS2 c.G1688T p.R563L DM? Colorectal cancer, non-polyposis 0.005813
GPC3 c.78_79insCCG p.P27delinsPP Not found Not found
18/B41 BRCA2 c.658_659delGT p.V220I* DM Breast and/or ovarian cancer 0.00006119
SLX4 c.G3337C p.G1113R Not found 0.000008237
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Table 2 Mutations in BC associated genes detected by NGS in a series of 45 Lebanese patients (Continued)
SMARCA4 c.C1098G p.I366M Not found 0.00002715
EPHX1 c.G1040C p.R347T Not found 0.00003296
19/B42 wwoxtv2 c.A544G p.K182E DM? cancer Not found
ATM c.A5558T p.D1853V DP Association with breast cancer,
contralateral
0.005186
RET c.C2508T p.S836S DP Association with thyroid cancer 0.04666
BRCA1 c.5090_5093delGTTA p.L1697fs Not found Not found
20/B43 PALB2 c.G2014C p.E672Q DM? Breast cancer? (common variant) 0.02239
PALB2 c.G2993A p.G998E DP Breast cancer (common variant) 0.01579
RAD51C c.G376A p.A126T FP Reduced activity 0.003529
Tp53 c.673-36G > C DFP Breast cancer Not found
21/B44 SLX4 c.G421T p.G141W DM Breast and/or ovarian cancer 0.0008237
SLX4 c.C1919A p.T640N Not found Not found
FANCM c.A5224G p.I1742V Not found 0.008398
POLD1 c.G2793C p.K931N Not found Not found
22/B45 ATM c.A5071C p.S1691R DM Ataxia telangiectasia 0.002019
BRIP1 c.G2220T p.Q740H DM? Breast and/or ovarian cancer 0.0004614
RET c.C2508T p.S836S DP Association with thyroid cancer 0.04666
FANCA c.A796G p.T266A DP Associated with breast cancer 0.5166
23/B46 BARD1 c.1071_1091del p.357_364del Not found Not found
FANCA c.C3412G p.L1138V Not found 0.001533
MRE11A c.A1728T p.R576R Not found 0.000008238
SLX4 c.C1186G p.L396V Not found Not found
37/B47 SLX4 c.A5501G p.N1834S Not found 0.005542
ERCC4 c.G1633C p.G545R Not found 0.000008243
38/B48 SDHC c.C31T p.R11C Not found 0.000008252
FANCD2 c.A1348G p.I450V Not found 0.0003871
FANCF c.C959T p.P320L Not found 0.01264
TSC2 c.A2834G p.K945R Not found Not found
DIS3L2 c.1651_1652insGGG
p.A551delinsGA
Not found Not found
GNAS c.C1046T p.P349L Not found Not found
24/B49 BRCA1 c.C4327T p.R1443* DM Breast cancer Not found
MSH2 c.C1045G p.P349A DM Renal cell carcinoma 0.00009062
MSH2 c.G965A p.G322D DM? Colorectal cancer, non-polyposis 0.01411
BARD1 c.G253T p.V85L Not found 0.001068
NBN c.G340T p.V114F Not found Not found
RET c.C2249G p.A750G Not found 0.000008238
XRCC3 c.C260T p.P87L Not found 0.00006286
25/B50 POLH c.A2074G p.T692A DM Xeroderma pigmentosum 0.0001824
Tp53 c.673-36G > C DFP Breast cancer Not found
CTNNB1 c.A2315G p.N772S Not found 0.00003355
POLD1 c.C519G p.S173R Not found 0.009212
26/D1 ARL11 c.G446A p.W149X DP Association with cancer 0.009898
MSH2 c.T1182G p.F394L Not found 0.00001648
27/D4 CHEK2 c.T470C p.I157T DFP Li-Fraumeni syndrome Not found
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Nine truncating mutations were detected in 9 differ-
ent patients (Table 2). Three of these mutations were
DM in HGMD: The first woman carried p.R1443* in
BRCA1, the second one carried p.V220I* in BRCA2
and the third one carried p.G164X in ABCC12
(Table 2). The six remaining truncating mutations
were not found in HGMD: p.Q613X in SLX4, p.R170X
in ERCC3, p.Q117X in EZH2, p.P742fs in NSD1,
p.357_364del in BARD1 and p.L1697fs in BRCA1
(Table 2).
Three DM mutations were found, each one, in 2
different patients: p.C44F in BRCA1 (Families 13 and
30), p.P349A in MSH2 (Families 7 and 24) and p.G141W
in SLX4 (Fig. 1 and Table 2).
In some families where different variants were found,
in order to consider, which variant is pathogenic, we
analyzed the co-segregation of the variations found with
the cancer phenotype within 3 families 12, 13, and 32
(Figs. 1 and 2).
Two members of family 12 were diagnosed with BC,
their mother and maternal uncle were diagnosed with
primary lung cancer and bone cancer, respectively. The
nonsmoking mother was affected at the age of 63 but
the age of the maternal uncle at diagnostic was not
accessible. WES, in proband 12/B35 diagnosed with BC
at the age of 42, identified 2 variants including one DM?
p.I94L in RAD50, according to HGMD Professional
database, and one novel variation p.G191R in ARL11
Table 2 Mutations in BC associated genes detected by NGS in a series of 45 Lebanese patients (Continued)
28/D5 CDH1 c.G2387A p.R796Q Not found 0.00003300
29/D6 BUB1B c.A1535G p.E512G Not found 0.000008239
30/D7 APC c.C2876T p.S959F Not found Not found
BRCA1 c.G131T p.C44F DM Breast and/or ovarian cancer Not found
PRF1 c.G3A p.M1I DM Haemophagocytic lymphohistiocytosis,
familial
Not found
31/D8 TP53 c.G469A p.V157I DM Sarcoma, adult-onset 0.00005776
32/III_4 CDH1 c.G3A p.M1I DM Gastric cancer Not found
BRCA2 c.C4061T p.T1354M DM Breast cancer 0.000008328
BRCA2 c.G4258T p.D1420Y DM? Breast and/or ovarian cancer 0.006796
33/D12 CDH1 c.A160G p.R54G Not found 0.00005916
34/D13 BRCA2 c.G223C p.A75P DM? Breast cancer 0.0001650
DM disease-causing mutation, DM? likely disease-causing mutation, DP disease-associated polymorphism, FP in vitro or in vivo functional polymorphism, DFP
disease-associated polymorphism with additional functional evidence
Fig. 2 Pedigree of one family segregated for BRCA2 p.T1354M and CDH1 p.M1I variants. Filled squares (males) and circles (females) indicate the
affected individuals. + sign indicates the presence of the variant and – sign the absence of the variant in tested individuals
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(data not shown). Prediction tool Polyphen2 indicated
that both changes are benign and SIFT prediction tool
indicated that p.I94L in RAD50 is tolerated and that
p.G191R in ARL11 is damaging. Only p.I94L in RAD50
segregated in the affected sisters, diagnosed with BC at
the age of 48, but it was also found in their third youn-
gest 51 years old unaffected sister.
Three members of Family 13 were diagnosed with BC.
WES identified 3 DM according to HGMD Professional
database, including p.C44F in BRCA1, p.G141W in SLX4
and p.S404F in STK11 (Table 2). Leiden Open Variation
Database indicated that p.C44F in BRCA1 affects protein
function and it segregated with the disease (Table 3)
(Fig. 1).
Six members of family 32 were diagnosed with BC
(Fig. 2). Members III-3, III-4 and III-6 were diagnosed
with BC at the age of 56, 48 and 50, respectively. WES
in proband III-4 identified 2 relevant variants including
p.M1I in CDH1 and p.T1354M in BRCA2. Prediction
tool SIFT indicated that both changes are damaging and
are DM according to HGMD Professional database
(Table 2 and Fig. 2). The analysis of this family showed
that these variations were carried by affected and sib-
lings that are not affected to date (Fig. 2). However, they
were advised to join our screening program.
We have noted that the most frequently altered genes
involved in our familial cases are DNA repair genes
(Fig. 3a) and that some variants were recurrent in our
cohort: p.W149X in ARL11, p.S836S in RET, p.A126T in
RAD51C, p.T241M in XRCC3, p.G998E in PALB2 and
c.673-36G > C in TP53 (Table 2 and Fig. 3b). In four
cases, like the 4 families shown in Fig. 1, individuals ap-
pear to co-inherit multiple cancer causing or predispos-
ing gene mutations. Unlike, the old strategy where one
stops the investigation once a pathogenic mutation was
identified, NGS gives us the capability of collating all
known mutations/variants in a sample, which may per-
mit a more comprehensive understanding of the poly-
genic landscape model of cancer. An important question
to be answered is: Does an individual in Family 13 har-
boring all three DM mutation have different penetrance,
genotype to phenotype correlation, type or age of onset
of cancer than a sibling with only one DM variant? This
critical question can only be answered when we start to
combine all germline variant data of cancer patients and
their comprehensive phenotypes from around the world
in well-curated databases.
Discussion
We identified, in 45 patients with familial BC, 19 patho-
genic mutations that are DM mutations according to the
HGMD Professional database (Table 2). These 19 muta-
tions were found in 13 different genes including
ABCC12, APC, ATM, BRCA1, BRCA2, CDH1, ERCC6,
MSH2, POLH, PRF1, SLX4, STK11, and TP53. Six muta-
tions were found in BRCA1 and BRCA2 presenting a
lower prevalence (15.5%) of deleterious BRCA mutations
compared to the published literature [21–23].
In the Lebanese population, p.C44F mutation in the
BRCA1 gene was found twice in this study and 5 times
in previous studies [17, 18] in a total of 7 from 367 cases
studied (1.9%). In fact, 2 of 9 patients carried a
Table 3 BRCA variations found and their evaluations in BRCA databases
Gene Variation BIC database Clinically Importance/
Clinical Classification
COSMIC Leiden Open Variation Database
(LOVD)
BRCA Exchange
BRCA1 c.G131T p.C44F unknown/ pending Not found Affects function Not found
c.A536G p.Y179C unknown/ pending Not found Does not affect function Benign
c.C4327T p.R1443* yes/ class 5 Neutral Affects function Not found
c.A1067G p.Q356R unknown/ pending Pathogenic Does not affect function Benign
c.5090_5093delGTTA p.L1697fs Not found Not found Not found Not found
BRCA2 c.C65T p.A22V unknown/pending Not found Effect unknown Not found
c.G223C p.A75P unknown/ pending Not found Does not affect function Benign
c.658_659delGT p.V220I* yes/ class 5 Not found Affects function Not found
c.C4061T p.T1354M unknown/ pending Neutral Does not affect function Benign
c.G4258T p.D1420Y no/ pending Neutral Does not affect function Benign
c.C5744T p.T1915M no/ class 1 Neutral Does not affect function Not found
c.G8775C p.Q2925H unknown/ pending Not found Effect unknown Not found
c.A1114C p.N372H no/ class 1 Neutral Not found Benign
c.C1151T p.S384F no/ pending Not found Not found Benign
Descriptions of the classes in the BIC database:
Class 1: Not pathogenic/low clinical significance: There is significant evidence against this variant being a dominant high-risk pathogenic mutation
Class 5: Pathogenic: There is significant evidence to suggest that this variant is a dominant high-risk pathogenic mutation
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deleterious BRCA mutation in a cohort of 72 patients
and 3 of 14 patients carried a deleterious BRCA muta-
tion in a cohort of 250 patients. Our findings suggest it
is the most recurrent mutation in the Lebanese
population.
In families 23 and 35, we identified the truncating
mutation p.357_364del in BARD1 (Table 2). A previous
study, on this variation, showed the absence of co-
segregation with the disease and it was considered as
neutral polymorphisms [35]. We have observed this vari-
ant in our population and breast cancer patients and it
is recommended that a more thorough and functional
examination of this variant be conducted in the future.
In families 12, 13 and 32, we identified 7 variants in
ARL11, BRCA1, BRCA2, CDH1, RAD50, SLX4, and
STK11. The association of which variation towards
increasing predisposition to BC remains unknown.
Therefore, we analyzed the segregation of these varia-
tions and BC within the families. In family 13, only
p.C44F in BRCA1 segregated with BC in the family. In
family 12, p.I94L in RAD50 (a DM? mutation) was found
in affected and healthy sisters and could therefore not
lead to a conclusion regarding predisposition to BC. In
family 32, p.M1I in CDH1 and p.T1354M in BRCA2 are
implicated in gastric cancer and BC respectively and
knowing that the family presented with only BC, two hy-
pothesis can be formulated. First, III-6 can be considered
as phenocopy and second healthy, till now, sisters III-5,
III-7 and III-9 are at high risk (Fig. 2). In fact, in high-
risk families, women testing negative for the familial BRCA
mutation have an increased risk of BC and should be con-
sidered for continued surveillance [36]. Interestingly, two
Fig. 3 Frequencies of all variants in breast cancer predisposing genes from our 45 patients’ cohort (a) and the details of the most frequent
variants shown in (b)
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members of this family, III-4 and III-6 presented with
invasive lobular breast cancer (Fig. 2). The association
between CDH1 gene mutation and lobular cancer has been
well established previously [37], and it is not unrealistic to
suggest that this CDH1 variant may be the cause of lobular
breast cancer in this family.
The pathogenic status of the majority of novel substi-
tutions found and the 6 variations considered as DM?
according to HGMD professional, remains problematic
(Table 2). In fact, HGMD professional reports DM? as
likely pathological mutation reported to be disease
causing in the corresponding report, but the author has
indicated that there may be some degree of doubt, or
subsequent evidence has come to light in the literature,
calling the deleterious nature of the variant into ques-
tion [29]. Further studies are needed to define the
pathogenic status of the novel substitutions and the
DM? variations that have been found in our cohort of
patients with BC. These future studies have to be ana-
lyzed in a larger number of affected families and con-
trol population samples.
NGS and traditional sequencing methods are not pro-
ficient in detecting BRCA genomic rearrangements in-
cluding large deletions or duplications. Deletion and
duplication genomic rearrangements vary significantly
among countries and within ethnic groups [38]. We
admit, therefore, that our reported BRCA mutation
prevalence is underestimated.
Among the DM mutations found, several were associ-
ated with syndromes (Peutz-Jeghers), different cancer
types (renal cell carcinoma, gastric cancer) and with
diseases (Xeroderma pigmentosa, ataxia telangiectasia)
(Table 2). Clinically, none of the symptoms found in
these diseases were manifested in the different studied
families except for family 24. In this family, proband
24/B49 carried the mutation p.R1443* in BRCA1 and
two MSH2 variants (Fig. 1). Her mother had ovarian
cancer and her sister uterine cancer, both are deceased
and could not consequently be tested for these variants.
MSH2 mutation is reported in families with endomet-
rial cancer (Lynch syndrome) and breast cancer from
Kuwait [39].
This is the first application of NGS on BC in
Lebanon. In this study, we showed that the prevalence
of deleterious BRCA mutations (15.5%) is lower than
expected [17, 18] and that the overall mutation preva-
lence is equal to 40%, justifying the urgent need for
the adoption of high-throughput NGS technologies to
identify genes responsible for familial BC in the
Lebanese population. Indeed, additional to BRCA
mutations, highly penetrant mutations in genes associ-
ated with various hereditary cancer syndromes, such
as CDH1, TP53, MSH2, ATM and POLH were found in
the Lebanese population. Finally, we cannot rule out
that some of these families shift a putative explanation
towards a polygenic model where moderate and low
penetrance alleles, acting together, may play a pre-
dominant role [20, 40, 41]. Our findings support the
eligibility of performing genetic testing by massively
parallel sequencing on Lebanese familial BC cases.
Moreover, we would like to use this technology for
tumor genome sequencing, in order to identify som-
atic alterations, which would be a valuable guidance
towards individualized cancer therapy of Lebanese pa-
tients with BC. However, it is worthy of note that our
study reports a small number of variants that are clin-
ically actionable. Given the high rate of novel variants
identified in BRCA1/2 and other breast cancer-
associated genes, the clinical usefulness of the data is
currently limited. Unless larger and rigorous studies
are committed in this area of the world to correctly
classify variants identified here or in other studies, the
diagnosis and treatment of breast cancer will remain
suboptimal.
Conclusion
This is the first study that utilized NGS technology to
study genetic variants in 45 patients with familial breast
cancer from Lebanon. Our deleterious mutation preva-
lence was 40% with only 15.5% accounted for by the
BRCA1 and BRCA2 genes. This data should encourage a
different strategy for familial breast cancer genetic
screening in Lebanon, one that is based on WES rather
than the initial screening of BRCA1/2 genes. We report
here novel and rare variants in breast cancer predispos-
ing genes, which will be valuable to researchers and
clinicians around the world for variants’ classification
and patients’ care in general.
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